NZ patients contribute to research for future treatment for leukaemia in global studies

At the American Society of Haematology (ASH) conference, significant research on chronic lymphocytic leukaemia (CLL) was unveiled, capturing the attention of New Zealand’s haematologists and researchers. The studies focused on the extended monitoring of a chemo-free, fixed-duration, oral treatment approach for CLL patients, offering promising insights into a potentially groundbreaking first-line therapy. This research marks a pivotal advancement in understanding CLL treatment, highlighting the potential for more effective and manageable approaches in combating this form of leukaemia.

Please read more here: Media Release – Research for Future CLL Treatment